Amedeo Smart

Free Medical Literature Service


 

Amedeo

Diabetes

  Free Subscription

Articles published in
Kidney Int
    June 2024
  1. NANGAKU M
    SGLT2 inhibitor: 2-way superstar in nephrology?
    Kidney Int. 2024;105:1176-1177.
    >> Share

  2. KUME S, Packer M
    SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
    Kidney Int. 2024;105:1172-1176.
    >> Share

  3. YAU K, Cherney DZI, van Raalte DH, Wever BE, et al
    Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
    Kidney Int. 2024;105:1168-1172.
    >> Share

  4. MCEVOY CM, Yuen DA
    Not too much, not too little-just the right amount: the story of YAP in the podocyte.
    Kidney Int. 2024;105:1157-1159.
    >> Share

    May 2024
  5. HONG YA, Nangaku M
    Endogenous adenine as a key player in diabetic kidney disease progression: an integrated multiomics approach.
    Kidney Int. 2024;105:918-920.
    >> Share

  6. WANG L, Tian H, Wang H, Mao X, et al
    Disrupting circadian control of autophagy induces podocyte injury and proteinuria.
    Kidney Int. 2024;105:1020-1034.
    >> Share

    April 2024
  7. MURPHY DP, Wolfson J, Reule S, Johansen KL, et al
    A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease.
    Kidney Int. 2024 Apr 27:S0085-2538(24)00309-0. doi: 10.1016/j.kint.2024.
    >> Share

    March 2024
  8. NEGRI AL
    Sodium-glucose cotransporter 2 inhibitors in the treatment of refractory hypomagnesemia.
    Kidney Int. 2024;105:638.
    >> Share

  9. SHAH CV
    Sodium-glucose cotransporter 2 inhibition, epidermal growth factor, and magnesium homeostasis: is there a link?
    Kidney Int. 2024;105:638-639.
    >> Share

  10. CHEN JJ, Lee TH, Yang HY
    Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2024;105:442-444.
    >> Share

    February 2024
  11. CHEN J, Wang X, He Q, Yang HC, et al
    Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
    Kidney Int. 2024 Feb 27:S0085-2538(24)00160-1. doi: 10.1016/j.kint.2024.
    >> Share

    January 2024
  12. MUTO Y, Humphreys BD
    Leveraging multimodal chromatin profiling to identify a new potential driver of diabetic kidney disease.
    Kidney Int. 2024;105:25-27.
    >> Share

    December 2023
  13. FU EL, Mastrorilli J, Bykov K, Wexler DJ, et al
    A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Kidney Int. 2023 Dec 13:S0085-2538(23)00865-7. doi: 10.1016/j.kint.2023.
    >> Share

  14. SOURRIS KC, Ding Y, Maxwell SS, Al-Sharea A, et al
    Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
    Kidney Int. 2023 Dec 5:S0085-2538(23)00756-1. doi: 10.1016/j.kint.2023.
    >> Share

  15. LIZOTTE F, Rousseau M, Denhez B, Levesque D, et al
    Erratum to "Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease." Kidney Int. 2023;104:787-802.
    Kidney Int. 2023;104:1228.
    >> Share

  16. IWAGAMI M
    Post hoc analysis of the SONAR trial: potential analgesic effects of atrasentan?
    Kidney Int. 2023;104:1062-1064.
    >> Share

    November 2023
  17. EUN M, Kim D, Shin SI, Yang HO, et al
    Chromatin accessibility analysis and architectural profiling of human kidneys reveal key cell types and a regulator of diabetic kidney disease.
    Kidney Int. 2023 Nov 2:S0085-2538(23)00757-3. doi: 10.1016/j.kint.2023.
    >> Share

  18. FANG Z, Lee K, He JC
    A central role for mesangial cells in the initiation of diabetic nephropathy.
    Kidney Int. 2023;104:872-874.
    >> Share

    October 2023
  19. AZUSHIMA K, Kovalik JP, Yamaji T, Ching J, et al
    Abnormal lactate metabolism is linked to albuminuria and kidney injury in diabetic nephropathy.
    Kidney Int. 2023 Oct 5:S0085-2538(23)00565-3. doi: 10.1016/j.kint.2023.
    >> Share

    September 2023
  20. SMERKOUS D, Mauer M, Tondel C, Svarstad E, et al
    Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases.
    Kidney Int. 2023 Sep 27:S0085-2538(23)00675-0. doi: 10.1016/j.kint.2023.
    >> Share

    August 2023
  21. CHAN KW, Smeijer JD, Schechter M, Jongs N, et al
    Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
    Kidney Int. 2023 Aug 30:S0085-2538(23)00610-5. doi: 10.1016/j.kint.2023.
    >> Share

  22. SEN T, Ju W, Nair V, Ladd P, et al
    Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
    Kidney Int. 2023 Aug 3:S0085-2538(23)00537-9. doi: 10.1016/j.kint.2023.
    >> Share

    July 2023
  23. LIZOTTE F, Rousseau M, Denhez B, Levesque D, et al
    Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease.
    Kidney Int. 2023 Jul 26:S0085-2538(23)00502-1. doi: 10.1016/j.kint.2023.
    >> Share

  24. HONG S, Kim KS, Han K, Park CY, et al
    A cohort study found a high risk of end-stage kidney disease associated with acromegaly.
    Kidney Int. 2023 Jul 23:S0085-2538(23)00501-X. doi: 10.1016/j.kint.2023.
    >> Share

  25. MIMURA I, Nangaku M
    Epigenetic regulation of angiogenesis and ischemic response by long noncoding RNA LEENE in diabetes.
    Kidney Int. 2023 Jul 5:S0085-2538(23)00483-0. doi: 10.1016/j.kint.2023.
    >> Share

  26. HEERSPINK HJL, Jongs N, Neuen BL, Schloemer P, et al
    Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
    Kidney Int. 2023;104:181-188.
    >> Share

    April 2023
  27. CHAPMAN D, Judge PK, Sardell RJ, Staplin N, et al
    Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
    Kidney Int. 2023;103:787-790.
    >> Share

  28. CHEN Z, Zhu Z, Liang W, Luo Z, et al
    Reduction of anaerobic glycolysis contributes to angiotensin II-induced podocyte injury with foot process effacement.
    Kidney Int. 2023;103:735-748.
    >> Share

    February 2023
  29. TUTTLE KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, et al
    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo.
    Kidney Int. 2023 Feb 2:S0085-2538(23)00056-X. doi: 10.1016/j.kint.2022.
    >> Share

  30. CAZA TN, Larsen CP
    False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus.
    Kidney Int. 2023;103:425.
    >> Share

    January 2023
  31. FU EL, Kutz A, Desai RJ
    Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown.
    Kidney Int. 2023;103:30-33.
    >> Share

    December 2022
  32. RAYEGO-MATEOS S, Rodrigues-Diez R, Fernandez-Fernandez B, Mora-Fernandez C, et al
    Targeting inflammation to treat diabetic kidney disease: the road to 2030.
    Kidney Int. 2022 Dec 2:S0085-2538(22)01017-1. doi: 10.1016/j.kint.2022.
    >> Share

  33. WU H, Humphreys BD
    Immune cell heterogeneity in a mouse model of diabetic kidney disease.
    Kidney Int. 2022;102:1215-1216.
    >> Share

    November 2022

  34. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
    Kidney Int. 2022;102.
    >> Share

  35. ROSSING P, Caramori ML, Chan JCN, Heerspink HJL, et al
    Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.
    Kidney Int. 2022;102:990-999.
    >> Share

    October 2022
  36. BAKRIS GL, Ruilope LM, Anker SD, Filippatos G, et al
    Analysis from the FIDELITY study examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
    Kidney Int. 2022 Oct 28. pii: S0085-2538(22)00910.
    >> Share

  37. KRISHNAN S, Manoharan J, Wang H, Gupta D, et al
    CD248 induces a maladaptive unfolded protein response in diabetic kidney disease.
    Kidney Int. 2022 Oct 26. pii: S0085-2538(22)00904.
    >> Share

  38. LASSEN E, Bouchareb R, Daehn IS
    Podocyte as the link between sterile inflammation and diabetic kidney disease.
    Kidney Int. 2022;102:688-690.
    >> Share

    September 2022
  39. DE BOER IH, Khunti K, Sadusky T, Tuttle KR, et al
    Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
    Kidney Int. 2022 Sep 27. pii: S0085-2538(22)00634.
    >> Share

  40. FU J, Sun Z, Wang X, Zhang T, et al
    The single-cell landscape of kidney immune cells reveals transcriptional heterogeneity in early diabetic kidney disease.
    Kidney Int. 2022 Sep 12. pii: S0085-2538(22)00715.
    >> Share

  41. SPEER T, Schunk SJ
    Klotho in diabetic kidney disease: more than dust in the Wnt.
    Kidney Int. 2022;102:469-471.
    >> Share

  42. ZHAN P, Zhang Y, Shi W, Liu X, et al
    Myeloid-derived growth factor deficiency exacerbates mitotic catastrophe of podocytes in glomerular disease.
    Kidney Int. 2022;102:546-559.
    >> Share

    August 2022
  43. STEFANSSON VTN, Nair V, Melsom T, Looker HC, et al
    Molecular Programs Associated with Glomerular Hyperfiltration in Early Diabetic Kidney Disease.
    Kidney Int. 2022 Aug 30. pii: S0085-2538(22)00689.
    >> Share

  44. XIA Y, Coates PT, Nangaku M
    How does diabetes cause susceptibility to COVID in the kidney: new clues provided by organoids.
    Kidney Int. 2022 Aug 10. pii: S0085-2538(22)00608.
    >> Share

  45. SUZUKI Y, Kaneko H, Okada A, Matsuoka S, et al
    Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors.
    Kidney Int. 2022 Aug 4. pii: S0085-2538(22)00510.
    >> Share

  46. ZHANG J, Cai J, Cui Y, Jiang S, et al
    Corrigendum to Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, Chan J, Thalakola A, Le T, Xu L, Wang L, Jiang K, Wang X, Wang H, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R. "Role of the macula densa sodium glucose cotransporter type 1-neuronal nitri
    Kidney Int. 2022;102:448.
    >> Share

  47. RHEE EP
    Proteomic discovery in diabetic kidney disease-to what end?
    Kidney Int. 2022;102:236-238.
    >> Share

    July 2022
  48. ZENG W, Beyene HB, Kuokkanen M, Miao G, et al
    Lipidomic profiling in the Strong Heart Study identified American Indians at risk of chronic kidney disease.
    Kidney Int. 2022 Jul 16. pii: S0085-2538(22)00536.
    >> Share

  49. JAGANNATHAN G, Finkielstein VA, Markowitz GS, Kudose S, et al
    Armanni-Ebstein lesion in a diabetic patient with acute tubular injury.
    Kidney Int. 2022;102:213.
    >> Share

    June 2022
  50. SHAHZAD K, Fatima S, Khawaja H, Elwakiel A, et al
    Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease.
    Kidney Int. 2022 Jun 29. pii: S0085-2538(22)00513.
    >> Share

  51. TUTTLE KR, Agarwal R, Alpers CE, Bakris GL, et al
    Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease.
    Kidney Int. 2022 Jun 2. pii: S0085-2538(22)00436.
    >> Share


  52. Corrigendum to Fang Y, Chen B, Gong AY, et al. "The ketone body beta-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults." Kidney Int. 2021;100:1037-1053.
    Kidney Int. 2022;101:1301-1302.
    >> Share

    May 2022
  53. CHEN X, Tan H, Xu J, Tian Y, et al
    Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/beta-catenin signaling.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00378.
    >> Share

  54. MONTAGUD-MARRAHI E, Cuadrado-Payan E, Hermida E, Cacho J, et al
    Preemptive simultaneous pancreas kidney transplantation has survival benefit to patient.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00385.
    >> Share

  55. KOBAYASHI H, Looker HC, Satake E, Saulnier PJ, et al
    Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.
    Kidney Int. 2022 May 23. pii: S0085-2538(22)00372.
    >> Share

  56. LI H, Zhao X, Zheng L, Wang X, et al
    Bruceine A protects against diabetic kidney disease via inhibiting galectin-1.
    Kidney Int. 2022 May 19. pii: S0085-2538(22)00369.
    >> Share

  57. NAGAI Y, Matoba K, Takeda Y, Yako H, et al
    Rho-associated, coiled-coil-containing protein kinase 1 regulates development of diabetic kidney disease via modulation of fatty acid metabolism.
    Kidney Int. 2022 May 18. pii: S0085-2538(22)00370.
    >> Share

  58. PRUIJM M, Phan O, Zanchi A
    Metformin versus SGLT-2 inhibitors: how low can we go?
    Kidney Int. 2022;101:874-877.
    >> Share

  59. NISHI H
    Lay A TRAP for myeloid cell response in diabetic kidney disease.
    Kidney Int. 2022;101:872-874.
    >> Share

    April 2022
  60. XIE Y, E J, Cai H, Zhong F, et al
    Reticulon-1A mediates diabetic kidney disease progression through endoplasmic reticulum-mitochondrial contacts in tubular epithelial cells.
    Kidney Int. 2022 Apr 22. pii: S0085-2538(22)00336.
    >> Share

    March 2022
  61. CORREMANS R, Neven E, Maudsley S, Leysen H, et al
    Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats.
    Kidney Int. 2022 Mar 7. pii: S0085-2538(22)00176.
    >> Share

  62. PRESSLY JD, Ge M, Fornoni A
    LPCing through the nephron accelerates diabetic kidney disease.
    Kidney Int. 2022;101:454-456.
    >> Share

    February 2022
  63. HARUHARA K, Suzuki T, Wakui H, Azushima K, et al
    Deficiency of the kidney tubular angiotensin II type1 receptor-associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization.
    Kidney Int. 2022 Feb 28. pii: S0085-2538(22)00161.
    >> Share

  64. SASAKO T, Yamauchi T
    Addressing screams for evidence on renoprotection by GLP-1 receptor agonists.
    Kidney Int. 2022;101:222-224.
    >> Share

  65. XU Y, Fu EL, Clase CM, Mazhar F, et al
    GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
    Kidney Int. 2022;101:360-368.
    >> Share

  66. HONG Q, Cai H, Zhang L, Li Z, et al
    Modulation of transforming growth factor-beta-induced kidney fibrosis by leucine-rich -2 glycoprotein-1.
    Kidney Int. 2022;101:299-314.
    >> Share

    January 2022
  67. HASEGAWA S, Nangaku M
    SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
    Kidney Int. 2022;101:20-22.
    >> Share

    December 2021

  68. Corrigendum to Mann JFE, Muskiet MHA. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney Int. 2021;99:314-318.
    Kidney Int. 2021;100:1351-1352.
    >> Share


  69. Corrigendum to Wu L, Liu C, Chang D-Y, et al. Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy. Kidney Int. 2021;100:107-121.
    Kidney Int. 2021;100:1349-1350.
    >> Share

    November 2021
  70. YOSHIOKA K, Hirakawa Y, Kurano M, Ube Y, et al
    Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease.
    Kidney Int. 2021 Nov 29. pii: S0085-2538(21)01084.
    >> Share

  71. ZHANG J, Cai J, Cui Y, Jiang S, et al
    Role of the macula densa sodium glucose cotransporter type 1-nitric oxide synthase 1-tubuloglomerular feedback pathway in diabetic hyperfiltration.
    Kidney Int. 2021 Nov 26. pii: S0085-2538(21)01078.
    >> Share

  72. ANSERMET C, Centeno G, Bignon Y, Ortiz D, et al
    Dysfunction of the circadian clock in the kidney tubule leads to enhanced kidney gluconeogenesis and exacerbated hyperglycemia in diabetes.
    Kidney Int. 2021 Nov 24. pii: S0085-2538(21)01081.
    >> Share

  73. KAESLER N, Schreibing F, Speer T, Puente-Secades S, et al
    Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease.
    Kidney Int. 2021 Nov 10. pii: S0085-2538(21)01056.
    >> Share

  74. KUME S
    Ketone bodies: back to a place in the sun.
    Kidney Int. 2021;100:976-978.
    >> Share

    October 2021
  75. MOLLER-HACKBARTH K, Dabaghie D, Charrin E, Zambrano S, et al
    Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-kappaB signaling pathway.
    Kidney Int. 2021;100:809-823.
    >> Share

    September 2021
  76. HEERSPINK HJ, Cherney D, Postmus D, Stefansson BV, et al
    A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00865.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016